AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-11

Study Completion Date

2030-02-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or metastatic solid tumors. The main questions it aims to answer are:

* Which dosage of AD1208 is safe and tolerable for participants?
* What medical problems do participants have when taking AD1208?

Participants will:

* Take drug AD1208 every day up to 1 cycle at the least.
* Visit the site once every 1 weeks for checkups and tests during cycle 1 and every 3 weeks from cycle 2 onwards.
* Keep a diary of any adverse events and administrated drug

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors

NCT06872580

Advanced Solid Tumor

NOT_YET_RECRUITING PHASE1

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

NCT06949761

Solid Tumor

NOT_YET_RECRUITING PHASE1/PHASE2

L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00003430

Head and Neck Cancer Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

3D011-08 Monotherapy in Subjects With Advanced Solid Tumors

NCT05099536

Solid Tumor, Adult

WITHDRAWN PHASE1

A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors

NCT05601219

Solid Tumor, Adult

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

\- Dose-escalation Part The treatment cycle is defined as 21 days and AD1208 will be administered orally once or twice a day from Day 1 to Day 21 in every 21-day cycle. The dose-escalation part is divided into phase 1a, which determines the Recommended dose of AD1208 in monotherapy, and phase 1b, which determines the RP2D of AD1208 in combination therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor, Adult Tumor, Solid Solid Tumor Solid Tumor, Unspecified, Adult Solid Tumor Cancer Solid Tumors Refractory to Standard Therapy Solid Tumor in Advanced Stage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type DRUG

Up to 6 of cohorts will be applied sequentially in phase Ia part.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AD1208

Up to 6 of cohorts will be applied sequentially in phase Ia part.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female subjects ≥19 years of age
* Willing to consent to participate in study and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
* Histologically and/or cytologically confirmed any progressive, locally advanced (unresectable), or metastatic solid tumors that have relapsed or are refractory following the last line of treatment and for which prior standard therapy has been ineffective, standard therapy does not exist or is not considered appropriate.
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Life expectancy of at least 12 weeks
* Subjects with adequate hematologic, hepatic, and renal functions confirmed based on the screening laboratory test within 2 weeks prior to the first administration of IP.
* Female subject who is surgically sterile, is postmenopausal, or agrees to use a highly effective method of birth control (2 methods strongly recommended) during the study and for 6 months following the last dose of IP.
* Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or for the time the partner is breastfeeding throughout the study period and for 6 months after the final administration of IP.

Exclusion Criteria

* Untreated active brain metastases.
* has leptomeningeal disease.
* unrecovered \> Grade 1 from the adverse event of prior therapy except for alopecia.
* has an active autoimmune disease requiring systemic treatment within the past 2 years.
* Active interstitial lung disease (ILD) or pneumonitis or a history of ILD.
* Subject has received the following treatment;

* prior anticancer monoclonal antibody treatment or investigational therapy
* prior any chemotherapy
* prior radiotherapy
* Major surgery
* Clinically significant (i.e., active) cardiovascular disease
* known positive of human immunodeficiency virus (HIV) infection.
* Active hepatitis B or C subjects.
* known allergic reaction for active ingredients or inactive ingredients such as excipients of Investigational product.
* Live vaccine administered against infectious disease.
* Gastrointestinal (GI) track disease causing the inability to take oral medication, malabsorption syndrome or uncontrolled inflammatory GI disease.
* having psychiatric illness/social situations that would limit compliance with study requirements.
* women with a positive pregnancy test at screening test.
* women who are breast feeding.
* subject has any condition because of which, in the opinion of the investigator, the participation would not be in the best interest of the subject.

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No